Study #2020-1109
Immunotherapy with Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
MD Anderson Study Status
Enrolling
Treatment Agent
Pembrolizumab, Docetaxel, Cisplatin, Carboplatin
Description
This is a single arm phase II study that will evaluate the combination of pembrolizumab, docetaxel, and cisplatin or carboplatin (PDC) as single treatment modality in patients with stage II-IVb (T2-4, any N, M0) squamous cell carcinoma of the nasal cavity/paranasal sinuses (PNS SCC).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Squamous Cell Carcinoma, the Nasal Cavity, Paranasal Sinuses
Study phase:
Phase II
Physician name:
Renata Ferrarotto
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-866-407-7176
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.